Nasdaq rvnc

See all ideas. See all brokers.

Revance Therapeutics, Inc. About the company. The company's lead drug candidate is DAXXIFY DaxibotulinumtoxinA-lanm for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. Trading at Revenue is forecast to grow Trading at good value compared to peers and industry. Negative shareholders equity.

Nasdaq rvnc

.

Break of ascending triangle probably to happen. Past Performance.

.

Key events shows relevant news articles on days with large price movements. Karyopharm Therapeutics Inc. KPTI Evolus Inc. EOLS 1. Li Auto Inc.

Nasdaq rvnc

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. ZacksTrade and Zacks. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. OK Cancel. Add to portfolio.

Lindt ball calories

Keep track of upcoming events with our Earnings Calendar. How to buy Revance Therapeutics, Inc. Who knows. Health Technology. Strong sell Sell Neutral Buy Strong buy. Currently unprofitable and not forecast to become profitable over the next 3 years. Revenue to profit conversion. Price target decreased by 9. Debt level and coverage. Keep track of upcoming events with our Earnings Calendar. Beta 1Y.

.

Revance Therapeutics, Inc. High number of new directors Mar About the company. Employees FY. Employees FY. New minor risk - Share price stability Oct Trading at good value compared to peers and industry. Stock brokers. Like other stocks, RVNC shares are traded on stock exchanges, e. How to buy Revance Therapeutics, Inc. Volatile share price over the past 3 months. Announces Executive Changes Mar Currently unprofitable and not forecast to become profitable over the next 3 years. Will this area hold?